Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster.
The main objective of this study was to assess in 5-6-year-old French children (n=234) the persistence of antibodies induced by a primary series vaccination (at 2-4 months of age) and a first booster (at 12-16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac). The second objective was to evaluate in these 5-6-year-old French children the safety and the immunogenicity of a tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac) given as second booster.


RESULTS
Seroprotective antibody levels against diphtheria, tetanus, types 1-3 poliomyelitis and PRP were maintained 4-5 years after primary-vaccination and first booster with Pentavac. As expected, anti-PT antibodies levels were low, suggesting that children were not colonised by Bordetella pertussis. The second booster with Tetravac was well tolerated and elicited a strong booster response for all antigens.


CONCLUSIONS
acellular pertussis combined vaccine, used in primary-vaccination, could be considered as having the same priming effect and the same efficacy as whole cell pertussis vaccine.
Mallet
Eric
E
Hôpital Charles Nicolle, 1 rue Germont, 76031 Rouen, France.
Matisse
Noëlle
N
Mathieu
Nicolas
N
Langue
Jacques
J
Boisnard
Florence
F
Soubeyrand
Benoît
B
D000906:Antibodies / Q000032:analysis*; D000917:Antibody Formation / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D005260:Female; D005602:France / Q000453:epidemiology; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007156:Immunologic Memory / Q000276:immunology; D008297:Male; D023321:Poliovirus Vaccines / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology
D000906:Antibodies; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D023321:Poliovirus Vaccines; D017778:Vaccines, Combined